Research map: Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry

Back to the article

Papers in this map

  1. The Hospital Anxiety and Depression Scale · A. S. Zigmond · 1983 · 47368 citations · Cited by this paper
  2. Real-World Effectiveness and Safety of Anti-CGRP Monoclonal Antibodies in the Prevention of High-Frequency Episodic and Chronic Migraine in Romania—A Multicenter Retrospective Observational Study · Alin Ciubotaru · 2026 · Cites this paper
  3. Impact of semaglutide introduction on the use of triptans: an interrupted-time series · 2026 · Related
  4. EuroQol - a new facility for the measurement of health-related quality of life · The EuroQol Group · 1990 · 16023 citations · Cited by this paper
  5. Neck musculoskeletal dysfunction in patients with chronic primary headaches · 2026 · Related
  6. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition · 2018 · 10870 citations · Cited by this paper
  7. Selective reduction of thalamic glutathione in migraine in the absence of detectable N-acetylaspartate alterations · 2026 · Related
  8. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies · Erik B von Elm · 2007 · 10808 citations · Cited by this paper
  9. Identification of a resting-state functional brainstem network associated with trigeminal pain sensitivity and migraine · 2026 · Related
  10. A six-item short-form survey for measuring headache impact: The HIT-6™ · Mark R. Kosinski · 2003 · 1389 citations · Cited by this paper
  11. CD4+T cells mediate systemic and local immune changes and pain symptoms in the rat model of temporomandibular disorders related pain · 2026 · Related
  12. CGRP as the target of new migraine therapies — successful translation from bench to clinic · Lars IH Edvinsson · 2018 · 1039 citations · Cited by this paper
  13. Headache among children and adolescents in Benin: revised prevalence estimates, and estimates of attributed burden, from a national schools-based study · 2026 · Related
  14. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1) · Messoud Ashina · 2020 · 405 citations · Cited by this paper
  15. From tooth pain to trigeminal sensitization: translational models, experimental readouts, and mechanism-guided therapeutic opportunities in odontogenic and headache-related orofacial pain · 2026 · Related
  16. Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life · Dawn C. Buse · 2009 · 297 citations · Cited by this paper
  17. Peptidomics profiling identifies endogenous peptides associated with meningeal afferent activation in a chronic migraine mouse model · 2026 · Related
  18. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial · Messoud Ashina · 2022 · 164 citations · Cited by this paper
  19. Genetic regulation of cell type–specific chromatin accessibility contributes to migraine etiology · 2026 · Related
  20. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis · Roberta Maria Messina · 2023 · 154 citations · Cited by this paper
  21. Symptoms of autonomic dysfunction amongst those with acute post-traumatic headache due to mild traumatic brain injury · 2026 · Related
  22. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials · Faraidoon Haghdoost · 2023 · 154 citations · Cited by this paper
  23. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study · Stephen D. Silberstein · 2020 · 105 citations · Cited by this paper
  24. Assessment of Headache Diagnosis. A Comparative Population Study of a Clinical Interview With a Diagnostic Headache Diary · Dajuana Phillip · 2006 · 80 citations · Cited by this paper
  25. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials · Timothy Ryan Smith · 2021 · 48 citations · Cited by this paper
  26. Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society · Hans‐Christoph Diener · 2021 · 45 citations · Cited by this paper
  27. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention · Edoardo Caronna · 2024 · 42 citations · Cited by this paper
  28. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study · Messoud Ashina · 2023 · 28 citations · Cited by this paper
  29. Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache · Patricia Pozo‐Rosich · 2025 · 25 citations · Cited by this paper
  30. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial · Messoud Ashina · 2023 · 24 citations · Cited by this paper
  31. Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study · Yazan Bader · 2023 · 15 citations · Cited by this paper
  32. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany · Armin Scheffler · 2024 · 15 citations · Cited by this paper
  33. Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review · Pablo Irimia · 2024 · 14 citations · Cited by this paper
  34. Migraine treatment: Position paper of the French Headache Society · Xavier Moisset · 2024 · 14 citations · Cited by this paper
  35. Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study · Charles E. Argoff · 2024 · 13 citations · Cited by this paper
  36. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study · Michel Lantéri‐Minet · 2023 · 12 citations · Cited by this paper
  37. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study · Piero Barbanti · 2024 · 11 citations · Cited by this paper
  38. Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study · Paul Triller · 2024 · 11 citations · Cited by this paper
  39. A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II) · Piero Barbanti · 2025 · 11 citations · Cited by this paper

Source: OpenAlex (CC0)